All News
Filter News
Found 978 articles
-
The Danish vaccine maker’s respiratory syncytial virus candidate did not meet all primary endpoints in a late-stage study in older adults and the company is discontinuing the program.
-
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
7/20/2023
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.
-
Emergent BioSolutions Announces CEO Transition
6/27/2023
Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today announced that Robert G. Kramer Sr. has informed the Board of Directors of his intention to retire from Emergent.
-
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors
6/13/2023
Alkermes plc issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.
-
Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation
6/8/2023
Alkermes plc (Nasdaq: ALKS) (the Company) today announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission (SEC) in connection with the Company's upcoming 2023 annual general meeting of shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023.
-
$12+ Billion Influenza Vaccines Market to Grow at 7+% CAGR, Globally, by 2028 Lead by Quadrivalent Vaccines Segment with 88.36% Market Share in 2022 | The Insight Partners
5/30/2023
The Insight Partners published latest research study on "Influenza Vaccines Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028
-
Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value
5/25/2023
Alkermes plc filed its definitive proxy statement with the U.S. Securities and Exchange Commission and issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.
-
Lyophilization Services for Biopharmaceuticals Market to Reach $3.58Bn by 2028 with Lyophilization Cycle Development Segment Driving Growth During 2023–2028 | The Insight Partners
5/24/2023
The Insight Partners published latest research report on "Lyophilization Services for Biopharmaceuticals Market Size Report, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Service Type, and End User”, the global market size is projected to reach USD 3,586.55 million by 2028 from USD 2,051.41 million in 2022.
-
Indivior's Opvee is an emergency nasal spray medication to reverse opioid overdose approved for patients aged 12 years and above with signs of respiratory or central nervous system depression.
-
Blueprint Medicines, Indivior PLC and Lexicon Pharmaceuticals are all awaiting FDA decisions this week.
-
Influenza Vaccines Market (Vaccine Type, Virus Type) - Reach $12.27Bn by 2028 at 7.4% CAGR with Quadrivalent Vaccine Segment Driving Growth During 2022–2028 | The Insight Partners
5/22/2023
The Insight Partners published latest research report on "Influenza Vaccines Market Size Report, Share, Trends, Growth, Demand & Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group”, the global market size is projected to reach USD 12,272.49 million by 2028 from USD 7,478.53 million in 2021
-
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
5/15/2023
Emergent BioSolutions announced it has completed the sale of its travel health business to Bavarian Nordic.
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
5/11/2023
Emergent BioSolutions Inc. announced that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT.
-
Emergent BioSolutions Reports Financial Results For First Quarter 2023
5/9/2023
Emergent BioSolutions Inc. reported financial results for the first quarter ended March 31, 2023.
-
Travel Vaccines Market Revenue to Reach $ 5.91 Billion, Globally, by 2028 with 9.8% CAGR | The Insight Partners
5/9/2023
The Insight Partners published latest research report on "Travel Vaccines Market Size Report, Share, Trends & Growth Forecast to 2028 - COVID-19 Impact and Global Analysis By Product and Application”,
-
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
5/4/2023
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2023 financial results.
-
Gene Bio Medical Announces Partnership with Prairie Hub for Pandemic Preparedness
4/28/2023
Gene Biotechnology Enterprises Ltd, doing business as Gene Bio Medical, is proud to announce its partnership with the Prairie Hub for Pandemic Preparedness as a key commercialization partner.
-
Novozymes delivers stronger than expected Q1 results
4/26/2023
In the first three months of the 2023 financial year, Novozymes delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items.
-
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
4/19/2023
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023.
-
The FDA is set to decide on a Humira biosimilar and hold an Adcomm meeting for an Alzheimer’s agitation treatment. Also on its calendar for April are decision dates for two vaccine hopefuls.